NCT06671821CompletedPhase 2
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects
HRS-7535-202 Follow-up Study: A Long-term Evaluation of Safety, Tolerability, and Efficacy in Obese Subjects (Open-label, Extension Trial)
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
The Objective of this trial is to evaluate the long-term safety, tolerability, weight loss efficacy and metabolic benefits of HRS-7535 tablets inobesity.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- First submitted
- 23 Oct 2024
- Start date
- 20 Nov 2024
- Primary completion date
- 15 Aug 2025
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT06671821
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 81
- From 20 Nov 2024 to the primary completion date, 15 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.
Other
- Participants with poor compliance during the 36-week open-label extension treatment of the HRS-7535-202 trial;
- Pregnant, lactating, planning to conceive during the trial period, or fertile subjects unwilling to take effective contraceptive measures during the trial period.
Who the study is looking for
- Male or female subjects, 18-65 years of age at the time of signing informed consent;
- Subjects who have completed the entire 36-week treatment course of the HRS-7535-202 trial.
- Subjects who have a full understanding of the trial content, processes, and possible adverse reactions, and are capable and willing to comply with the protocol requirements to complete this study.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.